Lightpoint Medical


Contact David Tuch
Title CEO/Founder


Today, cancer surgery is frequently unsuccessful. For example, 1 in 4 prostate cancer patients will have cancer left behind after surgery. The high failure rate of cancer surgery is for the simple reason that surgeons do not have any way to detect cancer during surgery. The consequences are enormous including repeat operations, additional post-surgical treatment, worse survival outcomes, and increased healthcare costs.
Lightpoint Medical has developed a groundbreaking intra-operative molecular imaging technology to detect cancer during surgery. The technology is based on a recent discovery that PET imaging agents also emit an optical signal called Cerenkov Luminescence. This discovery has enabled Lightpoint to develop a portable molecular imaging scanner compact enough to be brought into the operating room. The lower cost also makes Lightpoint’s technology ideal for low-resource settings. The technology is applicable across a wide number of major cancer indications including stomach, colorectal, breast, prostate and lung cancer. Real-time detection of cancer during surgery will bring substantial health economic savings by reducing repeat operations, freeing-up operating room capacity, and reducing additional post-surgical treatment.
The company is supported by more than $7M in non-dilutive grant funding, $4M in equity funding led by Oxford Technology, and more than $1M from NHS England. Lightpoint’s lead product LightPath™ will be launched in summer 2015.

Company News

CROWDFUNDING: The 5 most successful crowdfunding campaigns in 2017

DateJan 6, 2018
2017 was a banner year for crowdfunding campaigns. Here are five of the most successful crowdfunding campaigns last year that you need to know about.

Lightpoint Medical Announces Global License Agreement With the University of Arizona

DateMay 17, 2016
Lightpoint Medical Announces Exclusive Global License Agreement With the University of Arizona to Develop Molecular Imaging Technology. The licensing process was facilitated by Tech Launch Arizona, the office of the UA that commercializes inventions stemming from University research.

Lightpoint Medical receives 2.4M Euro grant

DateNov 26, 2015
Lightpoint Medical Receives 2.4M Euro Grant to Support Clinical Study Aiming to Cut Breast Cancer Re-Operation Rates. Lightpoint Medical will evaluate the LightPath™ Imaging System as a means of identifying cancer in a study involving over 300 breast cancer patients involving several hospitals in the UK, Germany, and France.

Lightpoint Medical's LightPathTM Imaging System is CE marked

DateOct 19, 2015
Lightpoint Medical, an innovative medical device company specializing in imaging technologies, announced today that the LightPath™ Imaging System is now CE marked, enabling the launch of the device in Europe. ... "Bringing LightPath™ to market is an important milestone in our efforts to transform cancer surgery."